LABORATORY RESEARCH USE ONLY. NOT INTENDED FOR CONSUMPTION.

CJC-1295 with DAC — Published Research

Reviewed by: Elizabeth D.| Last updated: abril 29, 2026|For laboratory reference only

← Back to CJC-1295 with DAC product page

How to read this CJC-1295 with DAC research page

This page summarizes CJC-1295 with DAC literature by experimental theme, including albumin-binding chemistry, modified GRF analog design, and model-system pharmacokinetic research. It is a literature map, not a protocol or human-use resource.

  • Chemistry focus: references are organized around DAC linker behavior, albumin binding, and receptor-signaling models.
  • Research framing: summaries describe published experimental models and should not be read as product claims or intended uses.
  • Documentation links: compare the catalog listing, COA hub, y research framework.

Panda Peptides products are for research use only. No dosing, administration, reconstitution, treatment, hormone-use, or human-use guidance is provided.

Biblioteca de investigación

Published research on CJC-1295 with DAC — for educational purposes only

Drug Affinity Complex (DAC) Albumin-Binding Technology

The DAC technology utilizes a reactive maleimide linker attached to the peptide that covalently binds to Cys34 of circulating serum albumin. This prevents glomerular filtration (albumin MW ~66 kDa exceeds renal threshold) and protects the peptide from proteolysis. The conjugation reaction is essentially irreversible under physiological conditions. Pharmacokinetic studies in animal models show that >90% of CJC-1295-DAC becomes albumin-bound within minutes. For laboratory research use only.

Jette L et al. “hGRF(1-29)-albumin bioconjugates activate GRF receptor signaling in rat models.” Endocrinology. 2005. PubMed

Receptor pharmacology overview

CJC-1295 is a modified GRF(1-29) analog that activates a class B receptor pathway in pituitary models. Receptor activation stimulates Gαs-mediated cAMP signaling and downstream secretory responses. The four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) confer resistance to DPP-IV cleavage and improve receptor binding affinity compared to native GRF(1-29). For laboratory research use only.

Teichman SL et al. “Prolonged signaling effects of CJC-1295, a long-acting GRF analog.” J Clin Endocrinol Metab. 2006. PubMed

CJC-1295 in GRF-knockout mouse models

Studies using GRF-knockout mice—which have severe GH deficiency, dwarfism, and virtually undetectable IGF-1—demonstrated that CJC-1295 exposure partially restored somatic growth. Exposure increased body weight, femur length, and pituitary GH mRNA expression. The results confirmed that the somatotroph population in GRF-KO mice retained functional target receptors capable of responding to exogenous GRF analogs despite the absence of endogenous upstream peptide signaling. For laboratory research use only.

Alba M et al. “Exposure of CJC-1295, a long-acting GRF analog, normalizes growth in the GRF-knockout mouse.” Am J Physiol Endocrinol Metab. 2006. PubMed

Continue reviewing CJC-1295 with DAC

Use the research references above alongside Panda’s batch documentation and catalog specifications.

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.

Reviewed by

Elizabeth D.

Research content reviewer focused on peptide literature review, documentation quality, and reference completeness.

Editorial Review

Reviewed by Elizabeth D. y James S. — Panda Peptides Research Team.

Last reviewed: May 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for controlled laboratory, analytical, or reference use and are not consumer products.